NCT05764811View on ClinicalTrials.gov

SGLT-2 Inhibitor Effects on Cardiac and Hepatic Metabolic Profiles for the Diabetes Patients Combined With Obesity

NACompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 6, 2020

Primary Completion Date

December 31, 2022

Study Completion Date

December 31, 2022

Conditions

Fatty Liver Disease

Interventions

DRUG

Canagliflozin 100mg

100 mg daily for a month

Trial Locations (1)

704

National Cheng Kung University Hospital, Tainan City

All Listed Sponsors

lead

National Cheng-Kung University Hospital

OTHER

NCT05764811 - SGLT-2 Inhibitor Effects on Cardiac and Hepatic Metabolic Profiles for the Diabetes Patients Combined With Obesity | Biotech Hunter | Biotech Hunter